It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The telomere repetitive TTAGGG motif at the ends of chromosomes, serves to preserve genomic integrity and chromosomal stability. In turn, genomic instability is a hallmark of cancer—implicating telomere disturbance. Prostate cancer (PCa) shows significant ancestral disparities, with men of African ancestry at the greatest risk for aggressive disease and associated genomic instability. Yet, no study has explored the role of telomere length (TL) with respect to ancestrally driven PCa health disparities. Patient- and technically-matched tumour-blood whole genome sequencing data for 179 ancestrally defined treatment naïve PCa patients (117 African, 62 European), we assessed for TL (blood and tumour) associations. We found shortened tumour TL to be associated with aggressive PCa presentation and elevated genomic instabilities, including percentage of genome alteration and copy number gains, in men of African ancestry. For European patients, tumour TL showed significant associations with PCa driver genes PTEN, TP53, MSH2, SETBP1 and DDX11L1, while shorter blood TL (< 3200 base pairs) and tumour TL (< 2861 base pairs) were correlated with higher risk for biochemical recurrence. Concurring with previous studies linking TL to PCa diagnosis and/or prognosis, for the first time we correlated TL differences with patient ancestry with important implications for future treatments targeting telomere dysfunction.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Sydney, Ancestry and Health Genomics Laboratory, Charles Perkins Centre, School of Medical Sciences, Faculty of Medicine and Health, Camperdown, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X)
2 University of Pretoria, School of Health Systems and Public Health, Faculty of Health Sciences, Pretoria, South Africa (GRID:grid.49697.35) (ISNI:0000 0001 2107 2298)
3 St Vincent’s Hospital, Department of Urology, Darlinghurst, Australia (GRID:grid.413105.2) (ISNI:0000 0000 8606 2560)
4 Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Endocrine and Tumor Molecular Biology Laboratory, Porto Alegre, Brazil (GRID:grid.8532.c) (ISNI:0000 0001 2200 7498)
5 Sefako Makgatho Health Science University, Dr George Mukhari Academic Hospital, Department of Urology, Medunsa, South Africa (GRID:grid.461049.e)
6 University of Sydney, Ancestry and Health Genomics Laboratory, Charles Perkins Centre, School of Medical Sciences, Faculty of Medicine and Health, Camperdown, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); University of Pretoria, School of Health Systems and Public Health, Faculty of Health Sciences, Pretoria, South Africa (GRID:grid.49697.35) (ISNI:0000 0001 2107 2298); University of Manchester, Manchester Cancer Research Centre, Manchester, UK (GRID:grid.5379.8) (ISNI:0000000121662407); University of Limpopo, Turfloop Campus, Faculty of Health Sciences, Sovenga, South Africa (GRID:grid.411732.2) (ISNI:0000 0001 2105 2799)